CpG oligodeoxynucleotides as TLR9 agonists: Therapeutic application in allergy and asthma

Gaurav K. Gupta, Devendra K. Agrawal

Research output: Contribution to journalReview articlepeer-review

75 Scopus citations


Unmethylated cytosine-phosphate-guanine (CpG) dinucleotides in microbial DNA sequences activate Toll-like receptor (TLR) 9, and previous studies have shown that oligodeoxynucleotides (ODNs) containing CpG in specific base sequence motifs (CpG ODNs) can reiterate the majority of the immunomodulatory effects produced by bacterial DNA. Many of the manifestations in allergic diseases are primarily due to T helper (Th)-2 cell-type responses. CpG ODNs can induce Th1 and T-regulatory (Treg) cell-type cytokines that can suppress the Th2 response. The therapeutic application of TLR9 has been explored extensively in recent years, and many studies are being conducted to assess the safety and efficacy of TLR9 agonists in various diseases, including atopic and infectious diseases, and cancer. Studies in murine models have shown that the development of atopic airway disease can be prevented by treatment with CpG ODNs. Various clinical trials are currently ongoing to determine the efficacy of CpG ODNs as a therapeutic tool for atopic diseases. In this review, we discuss the therapeutic application of CpG ODNs in allergy and asthma. CpG ODNs may be used alone or as an adjuvant to immunotherapy to treat these disorders.

Original languageEnglish
Pages (from-to)225-235
Number of pages11
Issue number4
StatePublished - 2010

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology
  • Biotechnology
  • Medicine(all)


Dive into the research topics of 'CpG oligodeoxynucleotides as TLR9 agonists: Therapeutic application in allergy and asthma'. Together they form a unique fingerprint.

Cite this